At BIO 2025 in Boston today, pharma and biotech leaders discussed the current state of AI in the drug development life cycle.

Amid those worries, I've been tracking prices every day for 11 key products likely to be hit by tariff-induced price increases, and the answer I've come to so far is this: Not so much, at least ...